New Developments in Oncological Treatment: Targeted Treatments and Immunotherapy

Journal Title: European Archives of Medical Research - Year 2021, Vol 37, Issue 1

Abstract

In the last 20 years, when we started to understand cancer biology better, targeted therapies and immunotherapies have been developed in systemic treatments and they have started to take their place as monotherapy or combined therapies in routine practice. Treatments that affect specific molecules are called targeted therapies. Monoclonal antibodies (mAbs), tyrosine kinase inhibitors (TKIs) and those affecting the proliferation cascade constitute the majority of targeted therapies currently used. mAbs are targeted molecules produced from a single B-cell clone by antigen exposure. Most immunotherapeutics currently in use are in the form of mAbs. The targets of mAbs that we frequently use in cancer treatment today are human epidermal growth factor receptor-2 (HER-2), epidermal growth factor receptor (EGFR), vascular endothelial growth factor, nuclear factor kappa-B ligand receptor activator, programmed death-1 and programmed death ligand-1. Treatments for tyrosine kinases, which play an important role in growth signal modulation, are used in many types of cancer. TKIs are small molecules and are used orally. The most commonly used TKIs are anti-angiogenic multikinase inhibitors. However by the EGFR and anaplastic lymphoma kinase inhibitors, a great progress has been made especially in the treatment of non-small cell lung cancer. Again BRAF/MEK, smoothened/hedgehog pathway, poly (ADP-ribose) polymerase, phosphoinositide 3-kinase, HER-2 inhibitors are other TKIs in use. The mammalian target of rapamycin pathway is also used as a target in many cancers. Immunotherapies are therapies that regulate the immune microenvironment, strengthening the immune system and allowing immune cells to fight against tumor cells. The effect of immunotherapy on cancer cells has been demonstrated by the high dose interferon, which was the first immunotherapy used. It consists of cancer vaccine, oncolytic viruses, ex vivo activated T-cell and natural killer cell transfer and immune checkpoint inhibitors. All these treatments contribute significantly to the survival and quality of life of patients with more antitumor efficacy. A large number of new molecules are being researched going forward, and promising advances in cancer treatment will continue.

Authors and Affiliations

Funda Yılmaz, Berna Öksüzoğlu

Keywords

Related Articles

Idiopathic Scrotal Calcinosis: A Review of the Literature with Seven Cases

Objective: Scrotal calcinosis is a rare benign disease characterized by calcified nodules on the scrotum skin. In this article, seven patients who were diagnosed as idiopathic scrotal calcinosis were reviewed with the re...

Intraductal Papilloma of Buccal Mucosa Minor Salivary Gland Origin

Ductal papillomas are rarely seen in salivary glands. They are largely classified under the term “ductal papillomas” and generally further categorized as intraductal papilloma, sialadenoma papilliferum, and inverted duct...

Elevated Neutrophil-to-Lymphocyte Ratio May Be Associated with Overactive Bladder Patients

Objective: Overactive bladder (OAB) may be interrelated with chronic inflammation. The aim of this study was to assess the role of neutrophillymphocyte ratio (NLR) levels in men and women with OAB symptoms. Methods: Bet...

Comparison of Neutrophil to Lymphocyte Ratio in Obstructive Sleep Apnea Syndrome Phenotypes

Objective: Our aim in this study was to compare the neutrophil to lymphocyte ratio (NLR) in rapid eye movement (REM) related obstructive sleep apnea (RRO) syndrome (OSAS) and position related OSAS (SRO) to habitual snore...

Cancer Susceptibility Syndromes in Childhood Cancer: Okmeydanı Experience

Objective: Childhood cancers form 2% of all cancers, and identified familial and genetic factors are responsible for only 5-15%. Determining the hereditary conditions that cause predisposition enables early detection of...

Download PDF file
  • EP ID EP693343
  • DOI 10.4274/eamr.galenos.2021.44153
  • Views 51
  • Downloads 0

How To Cite

Funda Yılmaz, Berna Öksüzoğlu (2021). New Developments in Oncological Treatment: Targeted Treatments and Immunotherapy. European Archives of Medical Research, 37(1), -. https://europub.co.uk/articles/-A-693343